⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 9, 2024Neurology

Samelisant (SUVN-G3031) - Topline Results from the Phase-2 Proof-of-Concept Double-blind, Placebo-controlled Study in Patients with Narcolepsy (P10-9.002)

Ramakrishna Nirogi Pradeep Jayarajan Vijay Benade Vinod Goyal Anil Shinde Jyothsna Ravula Satish Jetta Venkat Jasti

View at Publisher

Ask AI

Bookmark

Share

Key Points

Samelisant demonstrates safety and efficacy in narcolepsy, with implications for novel treatment options.
The Phase-2 trial included double-blind, placebo-controlled design ensuring robust results in patient care.
Double-blind, placebo-controlled study emphasizes methodological rigor in evaluating medications for narcolepsy.
Highlights the need for further exploration into samelisant's effects in narcolepsy and potential for real-world applications.

Implication

Phase-2 proof-of-concept trial found samelisant safety and efficacy in narcolepsy patients, suggesting potential for improved treatment.

Abstract

To evaluate the safety, and efficacy of samelisant (SUVN-G3031) in narcolepsy patients with and without cataplexy

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nirogi et al. (2024) studied this question.

synapsesocial.com/papers/68e6fcc5b6db643587677398 https://doi.org/10.1212/wnl.0000000000208309

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Samelisant (SUVN-G3031) for the Treatment of Cataplexy in Patients With Narcolepsy Type-one: Rationale and Study Design of a Phase-two Study (P6-14.008)Original Research · 2026
21171 Study Design and Rationale for a Phase-2 Study of Samelisant (SUVN-G3031) for the Treatment of Cataplexy in Patients with Type 1 NarcolepsyHuman Clinical Trial · 2026
30649 Samelisant Improves the Symptoms of Excessive Daytime Sleepiness in Narcolepsy: Results from a Phase-2 Study2024
41021 Samelisant: Clinician and Patient Global Impression from a Double-Blind, Phase-2 Study in Patients with Narcolepsy2024
50730 Samelisant (SUVN-G3031) Demonstrates Significant Reduction in Excessive Daytime Sleepiness in Patients with Narcolepsy: Phase-2 ResultsOriginal Research · 2026

More related papers

0756 Phase-3 Clinical Development of Samelisant: Rationale and Study Design for Treating Excessive Daytime Sleepiness in Patients with Narcolepsy2026
0637 Composite Response with Once-Nightly Sodium Oxybate: Symptom Improvement in Participants with Narcolepsy Type 12024
0646 Efficacy Outcomes Among Male and Female Participant Subgroups: A Post Hoc Analysis from REST-ON2024

More from Neurology

Recanalization After Acute Cervical Artery DissectionTue,
Differential Trajectories of Brain Atrophy in Multiple Sclerosis, MOGAD, and AQP4 + NMOSDTue,